Zepbound for sleep apnea: what the FDA approval and SURMOUNT-OSA actually showed (2026)

Why this approval is a first

Obstructive sleep apnea affects a large share of adults with obesity, and until the end of 2024 it had no approved drug treatment at all. The standard of care was mechanical: positive airway pressure devices (CPAP and relatives), oral appliances, positional therapy, or surgery — all of which work by physically holding the airway open or bypassing the problem, none of which treat the underlying driver. On December 20, 2024, the FDA approved tirzepatide (Zepbound) for moderate-to-severe OSA in adults with obesity — the first medication ever cleared for the condition [2].

This did not come from a marketing claim. It came from two purpose-built phase 3 trials, together called SURMOUNT-OSA, designed specifically to measure apnea — not weight — as the primary outcome [1].

What OSA is, and why weight drives it

Obstructive sleep apnea is repeated collapse of the upper airway during sleep. Each time the airway closes, breathing pauses or shrinks, oxygen dips, and the brain briefly rouses you to reopen it — often hundreds of times a night, usually without you remembering. The result is fragmented, non-restorative sleep, daytime sleepiness, and, over years, higher risks of high blood pressure, heart disease, stroke, and metabolic problems.

Weight is a central driver. Fat around the neck and throat narrows the airway and makes it more collapsible, while abdominal fat reduces lung volume and airway stability. That mechanical link is exactly why a drug that produces major weight loss can plausibly treat the apnea itself — not just the sleepiness — and why SURMOUNT-OSA set out to prove it with sleep studies rather than assume it [1].

What SURMOUNT-OSA measured

The program ran two double-blind, randomized, placebo-controlled trials in adults with moderate-to-severe OSA and obesity. Trial 1 enrolled people who were not using PAP therapy; trial 2 enrolled people who were using PAP. Participants received the maximum tolerated tirzepatide dose (10 mg or 15 mg) or placebo for 52 weeks. The primary endpoint was the change in the apnea-hypopnea index — the standard yardstick of apnea severity [1].

This two-trial design answered two different real-world questions: can the drug help someone who isn't on a device, and can it add benefit for someone who already is? Splitting them is why the approval language and the clinical takeaway are more credible than a single mixed study would have been.

The numbers

At baseline participants had severe disease — mean AHI of 51.5 events per hour in trial 1 and 49.5 in trial 2, with mean BMI around 39 [1].

In trial 1 (no PAP), the AHI fell by 25.3 events per hour with tirzepatide versus 5.3 with placebo — an estimated treatment difference of 20.0 events per hour (P<0.001). In trial 2 (on PAP), the AHI fell by 29.3 events per hour with tirzepatide versus 5.5 with placebo — a treatment difference of 23.8 events per hour (P<0.001) [1].

Beyond apnea counts, tirzepatide also improved body weight, hypoxic burden (how much oxygen levels dropped during sleep), high-sensitivity C-reactive protein (an inflammation marker), systolic blood pressure, and patient-reported sleep outcomes. The most common side effects were gastrointestinal and mostly mild to moderate — the familiar GLP-1 profile [1].

What it means in practice

A 20-plus-event-per-hour reduction is clinically large — enough to move many people from severe to mild disease. But the honest framing is 'major improvement,' not 'cure.' The average participant still had residual apnea at 52 weeks, which is why the approval sits alongside, not instead of, established therapy. For someone who cannot tolerate CPAP, that is a genuinely new option; for someone doing well on a device, it may reduce disease burden and cardiovascular risk factors at the same time [1].

It is also a reminder that OSA and obesity are mechanically linked. Weight loss has always helped apnea; what is new is a drug with a trial designed to prove the apnea benefit directly, at a magnitude large enough for regulators to grant a specific indication.

The bottom line

If you have moderate-to-severe obstructive sleep apnea and obesity, tirzepatide is now an evidence-backed, FDA-approved medical option — the first drug ever approved for the condition. It is not a device replacement to assume on your own, and it is not for mild apnea or snoring. Bring your sleep-study results to a clinician who treats both sleep and obesity, and ask whether the OSA indication changes your treatment plan and your coverage.